Skip to Content
Søk Menu
Vi dekker

ESMO I European Society for Medical Oncology

ESMO 2025

ESMO-kongresside

  • / marie

Artikler fra ESMO 2025

Medtalks fra ESMO 2025

ESMO 2024

ESMO-kongresside

  • / marie

ESMO Norsk Aften 2025

BestPractice Nordic og Medmeet er glade for å kunne invitere til Norsk Aften ESMO 2025 i Berlin. Møt kollegene dine og få en oppsummering av nyheter og høydepunkter fra kongressen – etterfulgt av nettverksbygging og middag.

ESMO-kongresside

/ marie

Oncology • Meet the experts

Få tilgang

Abstracts fra ESMO 2024

ESMO-kongresside

  • / marie

ESMO 2023

ESMO 2023 • Meet the experts

Få tilgang

MEDtalks fra ESMO 2022

Endocrine Response for Routine Decision-making on Chemotherapy use in HR+/HER2-N0-1 Early Breast Cancer

/ Onkologi / Nadia Harbeck

Current landscape in the immuno-oncology treatment of non-melanoma skin cancers

/ Dermatologi / Paolo Antonio Ascierto

Sexual health in long-term breast cancer survivors

/ Onkologi / Solveig Katrine Smedsland

ICON trial update: Ipi+Nivo combination with chemotherapy does not improve survival

/ Fastleger / Jon Amund Kyte

The clinical value of circulating tumor DNA in renal cancer

/ Onkologi / Lars Dyrskjøt Andersen

Outstanding results of ovarian cancer treatment

/ Onkologi / Clare Scott

Optimizing the front-line PARP-inhibitor treatment of ovarian cancer from a Nordic perspective

/ Onkologi / Kristina Lindemann

Efficacy of trastuzumab-deruxtecan therapy in HER2-positive breast cancer

/ Onkologi / Angelika Starzer

ESMO Highlights: Promising data for the frontline treatment of gynecologic cancer

/ Onkologi / Kristina Lindemann

ESMO Highlights: Increase awareness of supportive and palliative care for patients with cancer

/ Onkologi / Christina H. Ruhlmann

ESMO Highlights: Practical changes for treatment of lower gastrointestinal tumors

/ Onkologi / Marco Gerlinger

First-line atezolizumab treatment significantly improves overall survival in patients with NSCLC and not eligible for a platinum-containing regimen

/ Onkologi / Siow Ming Lee

Prostatakreft – høydepunkter fra ESMO 2022

/ Onkologi / Daniel Heinrich

COSMIC-313 – the first metastatic renal cell carcinoma (RCC) phase 3 trial with a doublet nivolumab plus ipilimumab

/ Onkologi / Toni K. Choueiri

Two years of ADT reduce the risk of metastases in patients undergoing post-prostatectomy radiotherapy

/ Onkologi / Chris Parker

Abstracts fra ESMO 2022

MCED blood test – a gamechanger for early cancer detection

/ BestPractice Nordic
ESMO22Kreft

Air pollution and lung cancer in never-smoking people 

/ BestPractice Nordic
ESMO22Lungekreft

Tumor-infiltrating lymphocytes improves PFS in metastatic melanoma

/ BestPractice Nordic
ESMO22Melanom

Combination of abemaciclib and trastuzumab +/- fulvestrant improved OS in women with HR+, HER2+ advanced breast cancer  

/ BestPractice Nordic
BrystkreftESMO22

A major threat to human health

/ BestPractice Nordic
ESMO22Kreft

PARP inhibitors are showing promising results in treating ovarian cancer 

/ BestPractice Nordic
ESMO22Gynekologisk kreft
Load more
Prof. Gerard Zalcman

Firstline nivolumab plus ipilimumab shows durable OS after 4 years in patients with pleural mesothelioma

/ Gerard Zalcman
ESMO22Melanom Play the Video

Abstracts fra ESMO 2022

Doublet immune therapy for patients with localized renal cell carcinoma at high risk of relapse after nephrectomy 

  • / BestPractice Nordic

ESMO 2022 –» Understanding the disease to provide better care for cancer patients»  

/ Onkologi / BestPractice Nordic
Se oversigt

ESMO 2021 • Highlights

ESMO-kongresside

  • / marie

Back to top